Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment adult and pediatric patients with rare cancers, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as QN-302, QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, we are committed to providing exciting new therapeutic technologies to physicians and patients.
Ticker:
QLGN
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
1996
Main Therapeutic Focus:
Oncology
Lead Product in Development:
QN-302
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
